RESEARCH NOTICE & LEGAL DISCLAIMER

FOR RESEARCH PURPOSES ONLY. All information provided within the Biolabs Peptides Research Centre is intended strictly for scientific, laboratory, and educational purposes.

Not Medical Advice: The protocols and data presented herein do not constitute medical advice, nursing advice, or a professional healthcare diagnosis.
Non-Therapeutic: These peptides are not intended to diagnose, treat, cure, or prevent any medical condition or disease.
Researcher Responsibility: Any research conducted should be performed by qualified professionals in a controlled laboratory environment. By accessing this data, you acknowledge that you are responsible for following your local laws and institutional safety guidelines.

snap-8
10mg

SHOP VIALS

HIGHLIGHTS

SNAP-8

Research Protocol (10 mg Vial)

SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide originally developed as a cosmeceutical ingredient for anti-wrinkle effects[1][2]. It is an extended analog of the hexapeptide Argireline, designed to mimic part of the SNAP-25 protein involved in neuromuscular signaling[5]. By competitively inhibiting SNAP-25 in the SNARE complex, SNAP-8 attenuates acetylcholine release at neuromuscular junctions, thereby relaxing facial muscle contractions without causing paralysis[1][5]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

SNAP-8 (10 mg) Dosage & Research Protocol

SNAP-8 (Acetyl Octapeptide-3) is a sophisticated synthetic peptide engineered for its anti-aging and wrinkle-reduction properties. As an improved analog of Argireline, it works by modulating the SNARE complex to relax facial muscles gently—softening expression lines without the total paralysis associated with traditional neurotoxins.

Quickstart Guide

Purpose: Targeted reduction of fine lines and deep expression wrinkles.
Concentration: Reconstitute with 3.0 mL of sterile water for a final concentration of ~3.33 mg/mL.
Standard Dosage: 330 mcg to 1,000 mcg daily, administered via topical serum
Measurement: On a U-100 insulin syringe, 1 unit = 33.3 mcg.

Dosing Schedule & Titration

For ease of use, follow this step-by-step titration schedule. This gradual approach ensures research stability and optimal skin-smoothing results.

Phase 1: Initial (Weeks 1–4) Daily Dose: 330 mcg Injection Volume into serum: 10 Units (0.10 mL)

Phase 2: Intermediate (Weeks 5–8) Daily Dose: 500 mcg Injection Volume into serum: 15 Units (0.15 mL)

Phase 3: Target (Weeks 9–12) Daily Dose: 1,000 mcg Injection Volume into serum: 30 Units (0.30 mL)

Phase 4: Maintenance (Weeks 13–16) Daily Dose: 1,000 mcg Injection Volume into serum: 30 Units (0.30 mL)

Reconstitution & Storage

Maintaining peptide integrity is vital for research efficacy. Follow these steps for preparation and longevity:

Reconstitution Steps

Clean the vial stopper with an alcohol swab.
Slowly inject 3.0 mL of bacteriostatic/sterile water against the inner wall of the vial.
Gently swirl or roll the vial until the powder is fully dissolved. Do not shake.

Storage Guidelines

Lyophilized (Dry): Store at −20 °C (−4 °F) for long-term stability.
Reconstituted (Liquid): Must be refrigerated at 2–8 °C (35.6–46.4 °F). Use within 30 days for maximum potency.
Note: Avoid repeated freeze-thaw cycles; protect from direct light.

Logistics: Supply Planning

Based on the daily protocol, here are the estimated supplies required for your research duration:

8-Week Protocol

SNAP-8 (10 mg): 3 Vials
U-100 Insulin Syringes: 56 Count
Bacteriostatic Water: 1 x 10 mL Bottle
Alcohol Prep Pads: 2 Boxes (100ct)

12-Week Protocol

SNAP-8 (10 mg): 6 Vials
U-100 Insulin Syringes: 84 Count
Bacteriostatic Water: 2 x 10 mL Bottles
Alcohol Prep Pads: 2 Boxes (100ct)

16-Week Protocol

SNAP-8 (10 mg): 8 Vials
U-100 Insulin Syringes: 112 Count
Bacteriostatic Water: 3 x 10 mL Bottles
Alcohol Prep Pads: 3 Boxes (100ct)

Mechanism of Action

SNAP-8 functions by mimicking a portion of the SNAP-25 protein. By competing for a position in the SNARE complex, it reduces the release of acetylcholine at the neuromuscular junction.

Non-Paralytic: Unlike Botox, which cleaves proteins to cause paralysis, SNAP-8 merely attenuates signaling, allowing for natural facial movement while decreasing wrinkle depth.
Superior Efficacy: Research indicates SNAP-8 is approximately 30% more active than its predecessor, Argireline.

Clinical Observations & Safety

Wrinkle Reduction: Studies have shown an average reduction in wrinkle depth of 35%, with some areas improving by up to 60% after 30 days of consistent use.
Tolerability: Highly tolerated in clinical settings. Minimal side effects are limited to temporary localized redness or minor swelling at the injection site.
Skin Health: Research subjects often report improved skin elasticity and a "refreshed" appearance within the first 2–4 weeks.

Best Practices for Administration

Injection Site: Subcutaneous fat layers (abdomen, thighs, or upper arms).
Rotation: Always rotate the injection site by at least one inch daily to prevent localized irritation.
Technique: Insert the needle at a 90° angle (or 45° if lean), inject slowly, and wait three seconds before withdrawing the needle.
Lifestyle Synergy: For best results, maintain high hydration levels and use a broad-spectrum SPF to protect the skin from photoaging during the protocol.

Disclaimer: This guide is for educational and research purposes only. SNAP-8 is not FDA-approved for human consumption. Always consult with a licensed professional before beginning any peptide research.